Semaglutide has been shown to trigger medullary thyroid cell carcinoma in rodents. When its clinical relevance to humans is unknown, the FDA advises not to administer this drug in Those people with a personal or household heritage of medullary thyroid carcinoma. Semaglutide also poses a risk of pancreatitis and dehydration. https://peptides54310.uzblog.net/the-5-second-trick-for-retatrutide-44686562